This is a preview of subscription content, log in via an institution to check access.
Reference
Lazzaro C, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study . ClinicoEconomics and Outcomes Research 5: 125-135, 11 Apr 2013. Available from: URL: http://dx.doi.org/10.2147/CEOR.S41850
Additional information
* COST-effectiveness Analysis of Nab-paclitaxel
** incremental cost-effectiveness ratio
Rights and permissions
About this article
Cite this article
New paclitaxel nabs the prize in Italy. PharmacoEcon Outcomes News 677, 7 (2013). https://doi.org/10.1007/s40274-013-0359-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0359-9